The IAS–USA Annual Update on HIV Management in Atlanta, Georgia

The IAS–USA Annual Update on HIV Management in Atlanta, Georgia

Registration Details

  • In-Person Registration: $70.00 (USD)
  • In-Person Registration ends: Thursday, April 18, 2024
  • In-Person Fellows: $25.00 (USD)
  • In-Person Fellows ends: Thursday, April 18, 2024


Michael S. Saag, MD
University of Alabama at Birmingham
Jeffrey L. Lennox, MD
Emory University School of Medicine


Carlos del Rio, MD
Emory University
Steven K. Grinspoon, MD
Harvard Medical School
Sandra A. Springer, MD
Yale University
Melanie Thompson, MD
Melanie A. Thompson, MD
Thacker & Thompson, MD
Kimberly A. Workowski, MD
Emory University

April 18, 2024

8:30 AM – 3:30 PM ET


Cobb Galleria Centre - Ballroom
2 Galleria Parkway
United States

Registration for catering purposes is closed. You are still welcome to register, provided space is available; however, lunch may not be available or you may be able to select from any remaining lunches.

Please note that this course has no virtual component; it is in-person only.

Last Modified: Apr 18, 2024 @ 12:39 PM

Program Description

This live course will be in person at the Cobb Galleria Centre. There will NOT be a simultaneous virtual component for this course, but the on-demand activity will be available a week following the course.

This in-person course will focus on recent advances in HIV medicine, including updates from Conference on Retroviruses and Opportunistic Infections (CROI) 2024, new antiretroviral formulations and strategies, new approaches to HIV cure, management of substance use disorder (SUD) in people with HIV, sexually transmitted infections (STIs), overview of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study, immunizations in adults with HIV, and will feature a case-based panel discussion on antiretroviral therapy.

We remain committed to closely monitoring the evolving state of the pandemic. We will ensure that our vaccination policy and mask guidelines align with the circumstances leading up to the course.

Assessment of Needs

Rapid advances in HIV disease management require the ongoing attention of practitioners involved in direct patient care. This course will address the implications of new information on strategies for the clinical management of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Learning Objectives

After participating in the activity, learners will be able to:

  • Implement the latest recommendations for initiating and changing antiretroviral therapy in particular clinical circumstances, such as comorbid conditions, coinfections, pregnancy, and issues in older patients
  • Describe the most current data from recent scientific conferences, including research on new and investigational antiretroviral drugs
  • Describe current basic science research on HIV cure for patients who inquire on progress
  • Describe the current epidemiology, clinical presentation, prevention, and management of relevant common sexually transmitted infections (STIs) in adults with HIV
  • Manage substance use disorders, including opioids, stimulants, and alcohol
  • Implement updated primary care recommendations, including for special and routine vaccinations
  • Integrate findings from the REPRIEVE trial into the treatment plans for adults with HIV

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content.


Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

  • Have a solid, working knowledge of HIV disease management
  • Provide comprehensive or specialty care for patients with HIV infection
  • Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 14 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.

Nursing Credits

Educational Review Systems is an approved approver of continuing nursing education by the ASNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 5.5 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.

Pharmacy Credits

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 5.5 contact hours (0.55 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-24-034-L02-P

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.


Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare


Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at or 415-544-9400.